Grifols S.A. (NASDAQ:GRFS) currently has a daily average trading volume of 1.33M but it saw 1695734 shares traded on Thursday. With a market cap of 11.08B USD, the company’s enterprise value now stands nearly at $23.32B. Stock’s current market price of $16.20 came falling about -0.55 while comparing to the previous closing price of $16.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.73 and as low as $13.40. In the recent trading on the day, stock has struck highest price mark of $16.63 while lowest mark touched by it was $16.08.
Taking a look at 20-day trading activity of Grifols S.A. (GRFS) gives us an average price of $17.78, while its current price level is -37.04% below from 52-week high level whereas it is 20.90% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $18.59 while that of 200 days or SMA-200 reads an average of $20.83. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.25% during that period while stretching the period over a month that decreases to 2.98%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.46 which implies that the stock is in oversold territory.
Grifols S.A. (GRFS)’s stock is currently under the radar of 5 analysts who are in consensus at a 12-month price target range of between $38.64 and $38.64 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $38.64 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $38.64. Average price target assigned by them is $38.64 which highlights an upside potential of 58.07% for the stock over that period. And to attain the median price target of $38.64 assigned by those analysts, stock has to add about 58.07% of value to its current levels.
Data by FactSet Research shows that 5 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 4 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the HSBC Securities which upgraded the stock as “Hold” in its note to investors issued on June 09, 2020, recommending a price target of for it. Citigroup downgraded its recommendation for the stock as a “Sell” from “Neutral” on June 09, 2020 while assigning a price target of . Citigroup issued its recommendations for the stock as it downgraded the price target for the stock is .
Over the week, GRFS’s stock price is moving -5.26% down while it is -16.02% when we observe its performance for the past one month. Year-to-date it is -30.44% down and over the past year, the stock is showing a downside performance of -24.12%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2020, when its quarterly earnings per share (EPS) of $0.34 beaten by the consensus estimate of $0.4 for the same. The company is expected to be releasing its next quarterly report in 11/10/2020, for which analysts forecasted an EPS of $0.35 while estimate for next year EPS is $1.37. For GRFS, analysts are forecasting an EPS-growth rate of 16.10% for current year and estimate for EPS growth in next year is 10.20%. In next quarter, company is expected to be making quarterly sales of $1.65 billion as analysts are expecting the sales for current fiscal year at $6.4 billion and seeing the company making $6.85 billion in sales next year. Moreover, analysts are in estimates of $1.58 billion for current-quarter revenue.
Currently, Grifols S.A.’s total number of outstanding shares is 684.14M with 0.00% of that held by the insiders while 53.68% of its common stock has been owned by the institutions. It has a price to earnings ratio (P/E ratio) of 27.02 while having a 10.73 of forward P/E ratio. Stock has a price to book (P/B) ratio of 4.55.
A filing at the U.S. Securities and Exchange Commission revealed that First Trust NYSE Arca Biotechnolo came shrinking its share ownership by 0.00% in the Grifols S.A. (GRFS) decreasing its stake to 1.50% with control over 0.0 shares in the company. As per SEC documents, First Trust NYSE Arca Biotechnolo shunned 3,932,384 of company’s common stock of worth $74.2 million as per recent closing price of the stock. First Trust NYSE Arca Biotechnolo is not the only institutional holder which restructured its stake in Grifols S.A., as American Funds EuroPacific Growth dumped 3,513,426 shares of worth $66.3 million to bring its holdings to a total of 0.0 shares. In the most recent quarter, Fidelity Funds SICAV – European G came rising its stake by 7.35% in the company and now holds 2.56 million or 0.98% of the company’s stake having worth of about 48.26 million.